These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20635903)

  • 1. Present state of target therapy for disseminated renal cell carcinoma.
    Waalkes S; Kramer M; Herrmann TR; Schrader AJ; Kuczyk MA; Merseburger AS
    Immunotherapy; 2010 May; 2(3):393-8. PubMed ID: 20635903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Rini BI
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic renal cell carcinoma: current standards of care.
    Thompson JA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():8-12. PubMed ID: 19948454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
    Rini BI; Sosman JA; Motzer RJ
    BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
    [No Abstract]   [Full Text] [Related]  

  • 7. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of locally advanced renal tumors].
    Sánchez Zalabardo D; Millán Serrano JA; De Pablo Cárdenas A; Cuesta Alcalá JA
    Actas Urol Esp; 2010 Feb; 34(2):134-41. PubMed ID: 20403277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK; Rini BI
    Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of metastatic renal cell carcinoma].
    Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
    Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
    BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK; Papadopoulos G
    J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
    Bellmunt J; Calvo E; Castellano D; Climent MA; Esteban E; García del Muro X; González-Larriba JL; Maroto P; Trigo JM
    Cancer Chemother Pharmacol; 2009 Mar; 63 Suppl 1():S1-13. PubMed ID: 19259675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.